SEC Filing Summary: Synaptogenix, Inc. (Form 8-K)
Business Context and Reporting Period
This Form 8-K was filed by Synaptogenix, Inc. on April 30, 2021. The registrant is an emerging growth company incorporated in Delaware. The report primarily addresses Item 9.01, detailing financial statements and exhibits related to a capital raise completed in January 2021.
Key Financial Metrics
The filing discloses the following specific financial data regarding a recent securities offering:
- Gross Proceeds: $14.0 million raised in January 2021.
- Offering Price: $1.50 per unit (comprising one share of Common Stock and associated warrants).
- Shares Issued: 9,335,533 shares of Common Stock and/or prefunded warrants.
- Warrant Details:
- Series E Warrants: 9,335,533 shares at an exercise price of $2.1275 per share (12-month term).
- Series F Warrants: 9,335,533 shares at an exercise price of $1.725 per share (5-year term).
The filing references an unaudited pro forma consolidated balance sheet as of December 31, 2020, but does not provide specific values for revenue, net income, operating cash flow, total debt, or liquidity ratios within the text of this report.
Material Changes
The primary material change reported is the capital structure adjustment resulting from the January 2021 sale of securities. The pro forma balance sheet incorporated by reference reflects the impact of the $14.0 million gross proceeds and the issuance of the associated warrants.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosures inherent in a capital raise. The document focuses strictly on the mechanics of the transaction and the filing of the pro forma balance sheet.
Investor Verification Checklist
- Verify the full unaudited pro forma consolidated balance sheet (Exhibit 99.1) to assess the company's post-offering liquidity and debt position.
- Confirm the exact number of prefunded warrants versus common shares issued to understand the immediate dilution impact.
- Review the terms of the Series E and Series F warrants for specific adjustment provisions that could affect future share counts.
- Check subsequent filings for the actual use of the $14.0 million in gross proceeds.